the demand for paediatric and neonatal testing kits is set to experience continued growth. The market’s upward trajectory is ...

“You have 20 to 40 different technology stacks that you integrate as best as you ... “That’s a very simple set of products ...

Masimo executives are back calling their consumer audio business Sound United, with a senior executive on a conference call ...

Apple and Masimo’s legal battle over the Apple Watch’s Blood Oxygen sensing feature continues this week as both firms meet in ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Approaching One Million Activated TiVo OS Smart TVs; On Track to Achieve Year-End Goal of Two Million Smart TVs Awarded DTS AutoStage Video Win with a ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Needham analyst Michael Matson reiterated a Buy rating on Enovis (ENOV – Research Report) today and set a price target of $65.00. Michael ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

The global non-invasive respiratory monitoring market is poised for substantial growth, projected to increase from an estimated valuation of USD 8.4 Billion in 2023 to USD 15.0 Billion by 2033, at a ...

Metro Boomin, whose legal name is Leland Wayne, has been accused of sexual assault in a lawsuit filed on Tuesday in Los ...

A lawsuit against pulse oximeter manufacturers and distributors is starting to create change. But experts say the FDA needs ...